COMP adopted the use of 1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene for prevention of poliomyelitis in patients with immunodeficiencies deemed at risk.
COMP adopts nine recommendations for orphan designation.
In a strategic meeting that was held in London early this month, the Committee for Orphan Medicinal Products (COMP), a body set up by the European Medicines Agency (EMA) to review applications from people or companies seeking 'orphan medicinal product designation', adopted a total of nine recommendations for orphan designation, including four designation applications for very rare forms of lipodystrophy.
